Novo says CagriSema shows greater weight loss than Lilly rival in diabetes patients
Novo said CagriSema cut weight 12.4% in a diabetes trial, topping Eli Lilly’s tirzepatide and matching blood-sugar control.
- On Monday, Novo Nordisk reported its experimental drug CagriSema achieved 12.4% weight loss in a late-stage trial, outperforming Eli Lilly's tirzepatide at 5 mg for weight reduction.
- CagriSema is a weekly injection combining cagrilintide and semaglutide, the active ingredient in Wegovy, though the drug fell short of Lilly's Zepbound earlier this year, marking a setback.
- In the REDEFINE 9 trial, adults receiving CagriSema 1 mg/1 mg lost 21% of their body weight at 68 weeks, compared with a 2% reduction for placebo recipients.
- Novo Nordisk filed an FDA application for CagriSema in December 2025, expecting a decision in the fourth quarter of 2026, while shares fell more than 4% amid analyst concerns.
- At its capital markets day on Monday, the company detailed a multi-year rollout for next-generation obesity injectables, targeting a launch of CagriSema early next year.
16 Articles
16 Articles
CagriSema bests tirzepatide for weight loss in adults with type 2 diabetes
CagriSema conferred a greater weight reduction than tirzepatide for adults with type 2 diabetes, and induced weight loss of 21% at 68 weeks for those with overweight or obesity without diabetes, according to topline results from two trials. Novo Nordisk announced data from the REIMAGINE 5 and REDEFINE 9 trials of different study populations. Both studies evaluated once-weekly injectable
CagriSema, a new generation pen still undergoing clinical trials, provided a higher average weight loss than the Mounjaro. The announcement was made on Monday by Danish pharmacist Novo Nordisk, a manufacturer of medicines such as Ozempic and Wegovy, who is leading the development of CagriSema, according to information from Reuters. Why is intestinal cancer increasing among young people? Understand what changes: Jehovah's Witnesses flexibility ru…
Novo says CagriSema tops Lilly rival in diabetes patients for weight loss - Regional Media News
Sept 21 (Reuters) - Novo Nordisk said on Monday its next-generation experimental drug, CagriSema, delivered an estimated average weight loss of 12.4% in a late-stage trial in patients with diabetes, outperforming Eli Lilly's rival drug. It has been seen as a successor to Novo's weight [...]
Patients lost 12.4 percent on a low dose of Cagrisema. It's more than with a competing means.
Coverage Details
Bias Distribution
- 62% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
